I&#x27;m glad this article calls out the CLL drug ibrutinib.  You hear a lot of people say &quot;why aren&#x27;t we making progress in treating cancer?&quot;.  Well we are, ibrutinib is a great example.<p>The clinical trial data I looked at a couple year ago is a little fuzzy, but basically if you had CLL and the 17p deletion, your chance of being alive after 2 years was ~25% (using the standard of care before ibrutinib).   In the ibrutinib clinical trial, 95%+ of 17p CLL patients were still alive after 2 years.<p>A <i>massive</i> jump forward in the treatment of cancer.